MedPath

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Phase 3
Active, not recruiting
Conditions
Kawasaki Disease
Interventions
Registration Number
NCT04078568
Lead Sponsor
Children's Hospital of Fudan University
Brief Summary

This study evaluates the efficacy of the addition of prednisolone to conventional initial treatment (intravenous immunoglobulin \[IVIG\] plus aspirin) in reducing coronary artery lesion in children with Kawasaki disease (KD) .

Detailed Description

This is a multicenter, open-label, blind-endpoints, randomized controlled trial at more than 10 hospitals in China. The investigators enrolled KD children diagnosed within 10 days of onset. Participants will be randomly assigned in a 1:1 ratio to the control group (receiving 2g/kg IVIG and 30 mg/kg aspirin) or the intervention group (receiving 2 g/kg IVIG, 30 mg/kg aspirin and additional 2 mg/kg prednisolone). Baseline characteristics of each participant will be collected, including sex, age of onset, height, body weight, subtype of KD, fever days before initial IVIG, echocardiographic findings at enrolment, and a series of pre-IVIG laboratory tests. Two-dimensional echocardiography will be performed at admission, 2 weeks, 1 month, 3 months, 6 months,and 12 months after onset of KD to assess the coronary artery lesions.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
3208
Inclusion Criteria
  • Meeting diagnostic criteria for Kawasaki disease (KD) released by American Heart Association (AHA) in 2017
  • Diagnosed before the tenth day of illness (with the first day of illness defined as the first day of fever)
  • Not treated with IVIG yet
  • Age ≥1 month
Exclusion Criteria
  • Z score of any coronary artery before initial treatment ≥10
  • Receiving steroids or other immunosuppressive agents in the previous 30 days
  • With a previous history of KD
  • Afebrile before enrolment
  • With suspected infectious diseases including sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella and influenza
  • With serious immune diseases such as immunodeficiency or chromosomal abnormalities

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
the standard groupIVIG1. IVIG 2g/kg once, given within 12 to 24 hours; 2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
the standard+prednisolone groupIVIG1. IVIG 2g/kg once, given within 12 to 24 hours; 2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness. 3. Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
the standard groupAspirin1. IVIG 2g/kg once, given within 12 to 24 hours; 2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
the standard+prednisolone groupAspirin1. IVIG 2g/kg once, given within 12 to 24 hours; 2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness. 3. Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
the standard+prednisolone groupPrednisolone1. IVIG 2g/kg once, given within 12 to 24 hours; 2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness. 3. Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
Primary Outcome Measures
NameTimeMethod
Percentage of coronary artery lesions(CAL) at one month of illnessat one month of illness

Two-dimensional echocardiography will be performed to evaluate CAL at 1 month of illness. The measurement of each patient included the diameter of the left main coronary artery (LMCA), the left anterior descending artery (LAD), the left circumflex coronary artery (LCX), and the proximal and middle segments of the right coronary artery (RCA). Z score of each coronary artery will be calculated(Journal of the American Society of Echocardiography, 2011, 24(1).). CAL is defined as z≥2of any coronary artery of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.

Secondary Outcome Measures
NameTimeMethod
Number of patients with serious adverse eventsfrom admission to 3 months of illness

This is a composite outcome, including death, hypertension, severe infection, allergic reactions, heart failure, thrombosis, etc.

Percentage of the need for additional treatmentfrom admission to discharge (about 2 weeks of illness)

Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Participants who have recurrent or persistent fever (axillary temperature ≥37.5°C or rectal temperature ≥38°C) after 36 hours of completion of initial IVIG infusion will be given additional treatment.

Duration of fever (hours) after initiation of initial IVIG infusionfrom initiation of initial IVIG infusion to the first record of being afebrile(defined as an axillary temperature <37.5 for more than 24 hours)

Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Participants with an axillary temperature \<37.5℃ (or rectal temperature \<38℃) for more than 24 hours are considered afebrile. Record the time of the initiation of IVIG infusion and the time of the body temperature first becoming normal.

Change in serum C-reactive protein (CRP) concentrationfrom admission to 72 hours after completion of initial IVIG infusion

CRP level is measured before initial IVIG infusion and 72 hours after completion of initial IVIG infusion.

Changes in z scores of LMCA throughout the study periodfrom admission to 12 months of illness

This is a repeated measurement. The internal diameter of LMCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).

Changes in z scores of the proximal segment of RCA throughout the study periodfrom admission to 12 months of illness

This is a repeated measurement. The internal diameter of the proximal segment of RCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).

Changes in z scores of the middle segment of RCA throughout the study periodfrom admission to 12 months of illness

This is a repeated measurement. The internal diameter of the middle segment of RCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).

Changes in z scores of LAD throughout the study periodfrom admission to 12 months of illness

This is a repeated measurement. The internal diameter of LAD will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).

Changes in z scores of LCX throughout the study periodfrom admission to 12 months of illness

This is a repeated measurement. The internal diameter of LCX will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).

Trial Locations

Locations (34)

Bengbu First People's Hopital

🇨🇳

Bengbu, Anhui, China

Anhui Children's Hospital

🇨🇳

Hefei, Anhui, China

Children's Hospital, Capital Institute of Pediatrics

🇨🇳

Beijing, Beijing, China

Children's Hospital of Chongqing Medical University

🇨🇳

Chongqing, Chongqing, China

Xiamen Children's Hospital

🇨🇳

Xiamen, Fujian, China

Lanzhou University Second Hospital

🇨🇳

Lanzhou, Gansu, China

Sun Yat-sen Memorial Hospital

🇨🇳

Guangzhou, Guangdong, China

Guangzhou Women and Children's Medical Center

🇨🇳

Guangzhou, Guangdong, China

Shenzhen Children's Hospital

🇨🇳

Shenzhen, Guangdong, China

Liuzhou Maternity and Children Healthcare Hospital

🇨🇳

Liuzhou, Guangxi, China

Kaifeng Children's Hospital

🇨🇳

Kaifeng, Henan, China

Henan Children's Hospital

🇨🇳

Zhengzhou, Henan, China

the First Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

The Third Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

Taihe Hospital Affiliated Hospital of Hubei University of Medicine

🇨🇳

Shiyan, Hubei, China

Union Hospital,Tongji Medical College of Huazhong University of Science and Technology

🇨🇳

Wuhan, Hubei, China

Hunan Provincial People's Hospital

🇨🇳

Changsha, Hunan, China

Inner Mongolia People's Hospital

🇨🇳

Hohhot, Inner Mongolia, China

Children's Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

Children's hospital of Soochow University

🇨🇳

Suzhou, Jiangsu, China

Xuzhou Children's Hospital

🇨🇳

Xuzhou, Jiangsu, China

Jiangxi Provincial Children's Hospital

🇨🇳

Nanchang, Jiangxi, China

The First Hospital of Jilin University

🇨🇳

Chang chun, Jilin, China

Shengjing Hospital of China Medical University

🇨🇳

Shenyang, Liaoning, China

Xi'an Children's Hospital

🇨🇳

Xi'an, Shaanxi, China

Qilu Hospital of Shandong University

🇨🇳

Jinan, Shandong, China

Qingdao Women and Children's Hospital (Liaoyang West Road)

🇨🇳

Qingdao, Shandong, China

Qingdao Women and Children's Hospital

🇨🇳

Qingdao, Shandong, China

Shanghai Children's Hospital

🇨🇳

Shanghai, Shanghai, China

Children's Hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

Sichuan Provincial People's Hospital

🇨🇳

Chengdu, Sichuan, China

Chengdu Women's and Children's Central Hospital

🇨🇳

Chengdu, Sichuan, China

Hangzhou First people's Hospital

🇨🇳

Hangzhou, Zhejiang, China

Yuying Children's Hospital of Wenzhou Medical University

🇨🇳

Wenzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath